At what stage is Cabergoline suitable for babies?

Cabergoline (Cabergoline) is a drug that is generally not suitable for use in infants or children. It is mainly used in adults to treat dopamine-related diseases, such as hyperprolactinemia, pituitary adenomas, and Parkinson's disease. Here's an explanation of why cabergoline is generally not suitable for use in infants and children:

1.Not suitable for use in children: Dosage and use guidelines for cabergoline generally apply only to adults. Physiological and metabolic processes in children differ significantly from those in adults, requiring special pediatric medical management. The dopamine system of infants and children is also constantly developing, so using cabergoline may have unpredictable effects on it.

2.Potential side effects: Cabergoline may cause a series of side effects, including headache, nausea, vomiting, hypotension, etc. These side effects may be more dangerous in children because their metabolic and pharmacodynamic responses to the drug are often less stable.

3.Lack of safety data in children: Due to ethical and legal reasons, clinical trials are not typically conducted in children, so there is a lack of sufficient safety data in children to support the use of cabergoline in children.

4.Alternative treatments: In cases where a child has a cabergoline-related condition, doctors will often look for alternative treatments to meet the child's specific medical needs. For example, hyperprolactinemia may be treated with other medications or surgical intervention in children.

Cabergoline is not currently available in the country, so patients cannot purchase it domestically and need to purchase cabergoline through overseas channels. In foreign countries, cabergoline is the original drug, and the cheaper version is the Turkish original drug, which costs about one to two hundred yuan.